共 61 条
[1]
Kyle RA(1995)Primary systemic amyloidosis: clinical and laboratory features in 474 cases Semin Hematol 32 45-59
[2]
Gertz MA(1997)The systemic amyloidosis N Engl J Med 337 898-909
[3]
Falk RH(1998)The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement QJM. 91 141-157
[4]
Comenzo RL(1997)A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine N Engl J Med 336 1202-1207
[5]
Skinner M(1988)Treatment of AL amyloidosis without myeloma Ann Med Int Paris 139 190-193
[6]
Dubrey SW(2004)Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case–control study Blood 103 3960-3963
[7]
Cha K(2004)High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study Ann Int Med 140 85-93
[8]
Anderson J(2005)High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement Int Med 44 484-489
[9]
Chamarthi B(2008)Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis NDT Plus 6 414-416
[10]
Reisinger J(2007)High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N Engl J Med 357 1083-1093